New study tracks real-world success of ribociclib combo for early breast cancer
NCT ID NCT06797531
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study looks at how well the drug ribociclib works with hormone therapy in everyday practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will follow about 177 patients in Saudi Arabia for several years to see if the cancer comes back and to check for side effects. The goal is to understand the real-world benefits and risks of this treatment combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11426, Saudi Arabia
Conditions
Explore the condition pages connected to this study.